FDA's Drugs@FDA database lists a supplement to NDA 215866, Eli Lilly's tirzepatide marketed as Mounjaro, picked up in the 23 September regulatory sweep; the record gives no action date. It does not state what the supplement covers — a labelling revision, a manufacturing change or something else.
Supplements are routine and frequent. Until the updated label is published, there is nothing here that changes prescribing. Tirzepatide is marketed in India; any Indian label change would come separately through CDSCO.
- No change to tirzepatide prescribing follows from this listing.
- Check the FDA label when the revised version is posted.
- Continue standard monitoring for gastrointestinal effects and dose titration.
Why it matters
Tirzepatide is widely prescribed, so label changes are worth watching for.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free